{
    "Trade/Device Name(s)": [
        "xTAG\u00ae CYP2D6 Kit v3"
    ],
    "Submitter Information": "Luminex Molecular Diagnostics, Inc.",
    "510(k) Number": "K130189",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "II",
    "Product Code(s)": [
        "NTI"
    ],
    "Summary Letter Date": "May 6, 2013",
    "Summary Letter Received Date": "May 7, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3360"
    ],
    "Regulation Name(s)": [
        "Drug Metabolizing Enzyme Genotyping Systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular"
    ],
    "Analyte(s)": [
        "CYP2D6 nucleotide variants",
        "CYP2D6 gene rearrangements"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [
        "Qualitative genotyping"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for xTAG CYP2D6 Kit v3 for qualitative genotyping of CYP2D6 gene variants and rearrangements from whole blood.",
    "Indications for Use Summary": "Simultaneously detects and identifies CYP2D6 nucleotide variants and gene rearrangements from genomic DNA extracted from EDTA or citrate anticoagulated whole blood as an aid to clinicians in determining therapeutic strategy for drugs metabolized by CYP2D6.",
    "fda_folder": "Toxicology"
}